Priority Research Papers:
Hypoxia-inducible factors enhance glutamate signaling in cancer cells
Metrics: PDF 2762 views | HTML 2562 views | ?
Hongxia Hu1,2,3, Naoharu Takano2,3, Lisha Xiang2,3,4, Daniele M. Gilkes2,3, Weibo Luo2,3,5, and Gregg L. Semenza2,3,5,6
1 Predoctoral Training Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD
2 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
3 Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD
4 Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China
5 Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD
6 Departments of Medicine, Oncology, Pediatrics, Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Gregg L. Semenza, email:
Keywords:AMPA receptor, clear cell renal carcinoma, hepatocellular carcinoma, HIF-1
Received: October 01, 2014 Accepted: October 15, 2014 Published: October 15, 2014
Signaling through glutamate receptors has been reported in human cancers, but the molecular mechanisms are not fully delineated. We report that in hepatocellular carcinoma and clear cell renal carcinoma cells, increased activity of hypoxia-inducible factors (HIFs) due to hypoxia or VHL loss-of-function, respectively, augmented release of glutamate, which was mediated by HIF-dependent expression of the SLC1A1 and SLC1A3 genes encoding glutamate transporters. In addition, HIFs coordinately regulated expression of the GRIA2 and GRIA3 genes, which encode glutamate receptors. Binding of glutamate to its receptors activated SRC family kinases and downstream pathways, which stimulated cancer cell proliferation, apoptosis resistance, migration and invasion in different cancer cell lines. Thus, coordinate regulation of glutamate transporters and receptors by HIFs was sufficient to activate key signal transduction pathways that promote cancer progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.